TENFU (06868) released its interim results, with a profit attributable to shareholders of 46.781 million yuan, a 4.03% decrease year-on-year.
Tianfu (06868) announced its interim results for 2026, with the group achieving revenue of 624 million yuan, a year-on-year decrease of 7.2%; the profit attributable to shareholders for the period was 46.781 million yuan, a year-on-year decrease of 4.03%; earnings per share were 0.04 yuan, and an interim dividend of 0.02 HKD per share is proposed.
TENFU (06868) announced its mid-term results for 2026, reporting revenue of 624 million yuan, a decrease of 7.2% year-on-year; the profit attributable to shareholders for the period was 46.781 million yuan, a decrease of 4.03% year-on-year; earnings per share were 0.04 yuan, and an interim dividend of 0.02 Hong Kong dollars per share is proposed.
The announcement stated that the decrease in the Group's revenue during the period was mainly due to the weak consumer market.
Related Articles
GAUSH MEDITECH (02407) has signed a five-year exclusive agency agreement with HEIDELBERG for the corneal confocal microscope T3.
.png)
Guangzhou Baiyunshan Pharmaceutical Holdings (600332.SH) subsidiary received the pharmaceutical registration certificate from Macau.
H World Group Limited Sponsored ADR (01179, HTHT.US) brand momentum accelerates into tangible growth, raising guidance to release value signals.
GAUSH MEDITECH (02407) has signed a five-year exclusive agency agreement with HEIDELBERG for the corneal confocal microscope T3.
Guangzhou Baiyunshan Pharmaceutical Holdings (600332.SH) subsidiary received the pharmaceutical registration certificate from Macau.
H World Group Limited Sponsored ADR (01179, HTHT.US) brand momentum accelerates into tangible growth, raising guidance to release value signals.
RECOMMEND
